Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ROSE 010

Next Previous
X
Search
Drug Profile

ROSE 010

Alternative Names: GTP-010; LY-307161 SR; ROSE-010

Latest Information Update: 08 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Eli Lilly and Company; Rose Pharma
  • Class Antihyperglycaemics; Glucagon-like peptides; Peptides
  • Mechanism of Action Glucagon-like peptide 1 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Dyspepsia; Irritable bowel syndrome; Type 2 diabetes mellitus

Most Recent Events

  • 08 Oct 2024 Rose Pharma plans a phase II ROSE-010 trial for Obesity and Overweight (Female) in USA (SC) in October 2024 (NCT06621017)
  • 22 Oct 2008 Efficacy and adverse events data from a phase IIa trial in Irritable bowel syndrome presented at the 16th United European Gastroenterology Week (UEGW-2008)
  • 22 May 2008 Final efficacy data from a phase II trial in Irritable bowel syndrome presented at Digestive Disease Week 2008 (DDW-2008)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top